ClinicalTrials.gg
TerminatedNCT05678959Updated Jan 13, 2026Results posted

Long-term Extension Study of Ligelizumab in Food Allergy

A Phase 3 interventional study of Ligelizumab 120 mg and Ligelizumab 240 mg in Food Allergy, sponsored by Novartis Pharmaceuticals. Terminated at 49 sites in 9 countries. Open to participants aged 6 Years to 57 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
163
Allocation
Non-randomized
Ages
6 Years to 57 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 139 studies in Food Hypersensitivity with a site in United States — 19 open to participants now, 28 under way, 3 of them phase 3. Food Hypersensitivity · United States.

Enrollment
20th of 105
163 · median 41
Started
2023
with 4 others
Phase 3
7 of 139
1 open now
Registered
118th of 139
by date
Lead sponsor
5 of 139
Novartis Pharmaceuticals

Among the 139 studies in Food Hypersensitivity with a site in United States, this one is the 20th largest by enrollment of the 105 interventional ones that give a count, is one of 5 that started in 2023, is one of 7 in phase 3, and was the 118th registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

19 of the 139 studies in Food Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 40 (77%) stop at 75 or younger; 44 take children under 18; 17 take healthy volunteers.

This study: 6 Years to 57 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Food Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.

Read the detailed description

This was a 3-year extension study with a 16-week follow-up period. The study enabled participants from planned multiple Phase III "core" studies to roll over to this extension study once the participants had completed predefined minimal requirements of a "core" study and agreed to consent to participate in this study.

Participants received ligelizumab treatment allocated in the core study, except for maximum responder (MR) participants performing conditional discontinuation of study treatment. Any participant considered a MR, as defined by an oral food challenge (OFC), performed conditional discontinuation of study treatment. This was to assess whether further treatment was still required because of disease modification by ligelizumab and/or a change in the underlying phenotype following the natural history of the disease (outgrowth of allergy) demonstrated by sustained unresponsiveness.

A subset of participants was offered administration of study treatment at home either by the participant him/herself (self-administration) or by parent/caregiver following training at three visits at the clinic.

03

Conditions studied

  • Food Allergy

Keywords

  • Food allergy
  • Peanut allergy
  • Oral food challenge (OFC)
  • Immunoglobulin E (IgE)
  • ligelizumab
04

Who can participate

Ages eligible
6 Years to 57 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed and or/assent (where applicable) obtained from participant/legal representative prior to enrolling in the rollover study and receiving study medication. If a minor participant providing assent reached the age of legal majority (as defined by local law), he/she was to be re-consented at the next study visit.
  • Participants had completed the treatment period in any ligelizumab's Phase III studies in food allergy.
  • Participants who were willing to adhere to the study visits and procedures, including receiving injections (study treatment) and participating in the OL-OFC (open label oral food challenge).
  • Participants who agreed to continue avoiding exposure to allergens (per core study) and any other foods they were allergic to throughout this study.
  • Participants who were able to safely continue into the study as judged by the investigator.

Key Exclusion Criteria:

  • Development of a severe or life-threatening episode of an allergic reaction that required intubation and/or intensive care unit (ICU) admission during the core studies.
  • Development of a serious adverse event which was suspected to be related to the study treatment judged by the investigator during the core study.
  • Development of uncontrolled asthma during the core study that compromised the safety of the participants judged by the investigator.
  • Development of cardiovascular, neurological, and or psychiatric conditions during the core study that could interfere with or compromise the safety of the participants, interfere with evaluation or interpretation of the study results or preclude completion of the study judged by the investigator.
  • Participants who failed to comply with the protocol requirements and procedures during the core study, and in the Investigator's opinion, should not participate in this extension study.
  • \<75,000/ul at end of treatment of the core study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Ligelizumab 120 mg

    Participants received ligelizumab 120 mg and matching placebo (to protect the dose blinding) every 4 weeks.

    Drug: Ligelizumab 120 mg

  • Experimental
    Ligelizumab 240 mg

    Participants received ligelizumab 240 mg every 4 weeks.

    Drug: Ligelizumab 240 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    TEAEs were defined as events where an AE either started after the first dose of extension study treatment and within 16 weeks after the last administered study treatment dose or began prior to the first dose of study treatment but increased in severity (based on preferred term) within 16 weeks after the last study treatment.

    Time frame: Up to approximately 81 weeks

Secondary outcomes

  1. Number of Participants Tolerating a Single Dose of More Than or Equal to 600 mg of Peanut Protein Without Dose-Limiting Symptoms

    Assessed during an open-label oral food challenge (OFC). If missing Week 52-OFC assessments, Week 156-OFC assessments were performed within 380 days (inclusive) after first extension dose date and considered as Week 52-OFC assessments.

    Time frame: Up to approximately 97 weeks

  2. Percentage of Participants With TEAEs and TESAEs, Assessed in Participants With at Least One Home Administration of Study Drug

    TEAEs were defined as events where an AE either started after the first dose of extension study treatment and within 16 weeks after the last administered study treatment dose or began prior to the first dose of study treatment but increased in severity (based on preferred term) within 16 weeks after the last study treatment.

    Time frame: Up to approximately 81 weeks

  3. Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Teenager Form (FAQLQ-TF)

    The FAQLQ-TF is a self-reported instrument designed for adolescents aged 13-17 to assess the impact of food allergy on health-related quality of life (HRQoL). The questionnaire includes three domains (emotional impact, allergen avoidance and dietary restrictions, and risk of accidental exposure). Each item was scored on a 7-point scale, with a higher score indicating greater impairment in HRQoL. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the impairment in HRQoL. OFC = oral food challenge.

    Time frame: Up to approximately 97 weeks

  4. Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Adult Form (FAQLQ-AF)

    The FAQLQ-AF is a self-reported instrument designed for adults aged 18-55 to assess the impact of food allergy on health-related quality of life (HRQoL). The questionnaire includes four domains (emotional impact, allergen avoidance and dietary restrictions, risk of accidental exposure, and food allergy-related health). Each item was scored on a 7-point scale, with a higher score indicating greater impairment in HRQoL. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the impairment in HRQoL. OFC = oral food challenge.

    Time frame: Up to approximately 97 weeks

  5. Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Teenager Form (FAIM-TF)

    The FAIM-TF is a self-reported instrument designed for adolescents aged 13-17. It aims to reflect the participant's perceived food allergy severity and food allergy-related risk. The questionnaire consists of six questions. The first four questions assess the participant's food allergy expectation outcomes, and the remaining two questions reflect aspects of the perceived severity of food allergy. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the perceived risk or chance of adverse events occurring. OFC = oral food challenge.

    Time frame: Up to approximately 97 weeks

  6. Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Adult Form (FAIM-AF)

    The FAIM-AF is a self-reported instrument designed for adults aged 18-55. It aims to reflect the participant's perceived food allergy severity and food allergy-related risk. The questionnaire consists of six questions; The first four questions assess the participant's food allergy expectation outcomes, and the remaining two questions reflect aspects of the perceived severity of food allergy. The total score was calculated as the arithmetic average of all completed items. the range for each item and the total score is from 1 (minimum) to 7 (maximum). The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the perceived risk or chance of adverse events occurring. OFC = oral food challenge.

    Time frame: Up to approximately 97 weeks

  7. Change From Baseline in the Medical Outcomes Study 36-item Short Form Version 2 Acute Version (SF-36v2) Physical Component Score (PCS) and Mental Component Score (MCS)

    The SF-36v2 Health Survey is a 36-item instrument that measures generic health-related quality of life. It contains 8 scales and 2 component summary indices evaluating physical, social, and emotional functioning in addition to general health perceptions and mental health. PCS and MCS scores range from 0 to 100, with higher scores indicating better health outcomes.

    Time frame: Up to approximately 97 weeks

07

Results

Posted Oct 30, 2025

Participant flow

Participant flow — Overall Study
MilestoneLigelizumab 120 mgLigelizumab 240 mg
Started8182
Completed00
Not completed8182
Withdrew: Study terminated by sponsor7676
Withdrew: Physician decision23
Withdrew: Adverse event11
Withdrew: Guardian decision10
Withdrew: Protocol deviation01
Withdrew: Subject decision10
Withdrew: Technical problem01

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

TEAEs were defined as events where an AE either started after the first dose of extension study treatment and within 16 weeks after the last administered study treatment dose or began prior to the first dose of study treatment but increased in severity (based on preferred term) within 16 weeks after the last study treatment.

Time frame:
Up to approximately 81 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
percentage of participantsLigelizumab 120 mgLigelizumab 240 mg
TEAEs84.069.5
TESAEs3.72.4
SecondaryNumber of Participants Tolerating a Single Dose of More Than or Equal to 600 mg of Peanut Protein Without Dose-Limiting Symptoms

Assessed during an open-label oral food challenge (OFC). If missing Week 52-OFC assessments, Week 156-OFC assessments were performed within 380 days (inclusive) after first extension dose date and considered as Week 52-OFC assessments.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Number of Participants Tolerating a Single Dose of More Than or Equal to 600 mg of Peanut Protein Without Dose-Limiting Symptoms
ParticipantsLigelizumab 120 mgLigelizumab 240 mg
Number of Participants Tolerating a Single Dose of More Than or Equal to 600 mg of Peanut Protein Without Dose-Limiting Symptoms1—
SecondaryPercentage of Participants With TEAEs and TESAEs, Assessed in Participants With at Least One Home Administration of Study Drug

TEAEs were defined as events where an AE either started after the first dose of extension study treatment and within 16 weeks after the last administered study treatment dose or began prior to the first dose of study treatment but increased in severity (based on preferred term) within 16 weeks after the last study treatment.

Time frame:
Up to approximately 81 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs and TESAEs, Assessed in Participants With at Least One Home Administration of Study Drug
percentage of participantsLigelizumab 120 mgLigelizumab 240 mg
TEAEs86.167.4
TESAEs5.60
SecondaryChange From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Teenager Form (FAQLQ-TF)

The FAQLQ-TF is a self-reported instrument designed for adolescents aged 13-17 to assess the impact of food allergy on health-related quality of life (HRQoL). The questionnaire includes three domains (emotional impact, allergen avoidance and dietary restrictions, and risk of accidental exposure). Each item was scored on a 7-point scale, with a higher score indicating greater impairment in HRQoL. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the impairment in HRQoL. OFC = oral food challenge.

Time frame:
Up to approximately 97 weeks
Reported as:
Mean · Unit on a scale
Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Teenager Form (FAQLQ-TF)
Unit on a scaleLigelizumab 120 mgLigelizumab 240 mg
Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Teenager Form (FAQLQ-TF)—1.13 ± NA
SecondaryChange From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Adult Form (FAQLQ-AF)

The FAQLQ-AF is a self-reported instrument designed for adults aged 18-55 to assess the impact of food allergy on health-related quality of life (HRQoL). The questionnaire includes four domains (emotional impact, allergen avoidance and dietary restrictions, risk of accidental exposure, and food allergy-related health). Each item was scored on a 7-point scale, with a higher score indicating greater impairment in HRQoL. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the impairment in HRQoL. OFC = oral food challenge.

Time frame:
Up to approximately 97 weeks
Reported as:
Mean · Unit on a scale
Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Adult Form (FAQLQ-AF)
Unit on a scaleLigelizumab 120 mgLigelizumab 240 mg
Change From Baseline in Total Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) Adult Form (FAQLQ-AF)0.32 ± 0.8730.29 ± 1.048
SecondaryChange From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Teenager Form (FAIM-TF)

The FAIM-TF is a self-reported instrument designed for adolescents aged 13-17. It aims to reflect the participant's perceived food allergy severity and food allergy-related risk. The questionnaire consists of six questions. The first four questions assess the participant's food allergy expectation outcomes, and the remaining two questions reflect aspects of the perceived severity of food allergy. The total score was calculated as the arithmetic average of all completed items. The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the perceived risk or chance of adverse events occurring. OFC = oral food challenge.

Time frame:
Up to approximately 97 weeks
Reported as:
Mean · Unit on a scale
Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Teenager Form (FAIM-TF)
Unit on a scaleLigelizumab 120 mgLigelizumab 240 mg
Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Teenager Form (FAIM-TF)—0.33 ± NA
SecondaryChange From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Adult Form (FAIM-AF)

The FAIM-AF is a self-reported instrument designed for adults aged 18-55. It aims to reflect the participant's perceived food allergy severity and food allergy-related risk. The questionnaire consists of six questions; The first four questions assess the participant's food allergy expectation outcomes, and the remaining two questions reflect aspects of the perceived severity of food allergy. The total score was calculated as the arithmetic average of all completed items. the range for each item and the total score is from 1 (minimum) to 7 (maximum). The possible range for the total score was 1 (minimum) to 7 (maximum). The higher the score, the greater the perceived risk or chance of adverse events occurring. OFC = oral food challenge.

Time frame:
Up to approximately 97 weeks
Reported as:
Mean · Unit on a scale
Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Adult Form (FAIM-AF)
Unit on a scaleLigelizumab 120 mgLigelizumab 240 mg
Change From Baseline in Total Scores in the Food Allergy Independent Measure (FAIM) Adult Form (FAIM-AF)-0.44 ± 0.3850.42 ± 1.296
SecondaryChange From Baseline in the Medical Outcomes Study 36-item Short Form Version 2 Acute Version (SF-36v2) Physical Component Score (PCS) and Mental Component Score (MCS)

The SF-36v2 Health Survey is a 36-item instrument that measures generic health-related quality of life. It contains 8 scales and 2 component summary indices evaluating physical, social, and emotional functioning in addition to general health perceptions and mental health. PCS and MCS scores range from 0 to 100, with higher scores indicating better health outcomes.

Time frame:
Up to approximately 97 weeks
Reported as:
Mean · Unit on a scale
Change From Baseline in the Medical Outcomes Study 36-item Short Form Version 2 Acute Version (SF-36v2) Physical Component Score (PCS) and Mental Component Score (MCS)
Unit on a scaleLigelizumab 120 mgLigelizumab 240 mg
PCS0.3 ± 5.037.0 ± 11.31
MCS0.0 ± 6.00-13.0 ± 21.21

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 16 weeks post treatment, up to a maximum duration of approximately 81 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ligelizumab 120 mg0/81 (0%)3/81 (3.7%)47/81 (58%)
Ligelizumab 240 mg0/82 (0%)2/82 (2.4%)43/82 (52.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventLigelizumab 120 mgLigelizumab 240 mg
ColitisGastrointestinal disorders1/810/82
Lip swellingGastrointestinal disorders1/810/82
NauseaGastrointestinal disorders1/810/82
Swollen tongueGastrointestinal disorders1/810/82
Swelling faceGeneral disorders and administration site conditions1/810/82
Type 1 diabetes mellitusMetabolism and nutrition disorders1/810/82
DyspnoeaRespiratory, thoracic and mediastinal disorders1/810/82
Pharyngeal swellingRespiratory, thoracic and mediastinal disorders1/810/82
Throat irritationRespiratory, thoracic and mediastinal disorders1/810/82
Pruritus allergicSkin and subcutaneous tissue disorders1/810/82
Most frequent other events
Showing 10 of 14
Most frequent other events
EventLigelizumab 120 mgLigelizumab 240 mg
NasopharyngitisInfections and infestations19/8117/82
Injection site erythemaGeneral disorders and administration site conditions7/8114/82
HeadacheNervous system disorders13/815/82
Upper respiratory tract infectionInfections and infestations12/8110/82
Injection site oedemaGeneral disorders and administration site conditions4/8111/82
InfluenzaInfections and infestations9/814/82
Injection site swellingGeneral disorders and administration site conditions2/817/82
COVID-19Infections and infestations6/817/82
CoughRespiratory, thoracic and mediastinal disorders6/813/82
Injection site indurationGeneral disorders and administration site conditions1/816/82

Baseline characteristics

The full analysis set (FAS) included all participants who enrolled into the extension study without screen-failure and who received at least one dose of study treatment during any core study.

Age, Continuous
Age, Continuous(years)Ligelizumab 120 mgLigelizumab 240 mgTotal
Mean19.4 ± 6.9518.9 ± 6.2319.2 ± 6.58
Age, Customized
Age, Customized(participants)Ligelizumab 120 mgLigelizumab 240 mgTotal
12 - 17 years414687
18 - 55 years403676
Sex: Female, Male
Sex: Female, Male(Participants)Ligelizumab 120 mgLigelizumab 240 mgTotal
Female373673
Male444690
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ligelizumab 120 mgLigelizumab 240 mgTotal
White5861119
Black or African American448
Asian121022
Multiple112
Not Reported6612
08

Study locations

49 sites
  • Allervie Clinical Research
    Birmingham, Alabama 35209, United States
  • Allergy and Immunology Associates
    Scottsdale, Arizona 85251, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Allergy and Asthma Associates of Santa Clara Vally Center
    San Jose, California 95117, United States
  • Allergy and Asthma Clin Res Inc
    Walnut Creek, California 94598, United States
  • UCHealth Outpatient Pavilion
    Aurora, Colorado 80045, United States
  • Asthma and Allergy Associates P C
    Colorado Springs, Colorado 80907, United States
  • Univ of South Florida Asthma Allergy and Immunology CRU
    Tampa, Florida 33613, United States
  • Childrens Healthcare of Atlanta
    Atlanta, Georgia 30342, United States
  • Atlanta Allergy and Asthma Clinic
    Marietta, Georgia 30062, United States
  • Ann and Robert H Lurie Childs Hosp
    Chicago, Illinois 60611, United States
  • Family Allergy and Asthma
    Lousiville, Kentucky 40217, United States
  • Johns Hopkins Childrens Center
    Baltimore, Maryland 21287, United States
  • Boston Childrens Hospital
    Boston, Massachusetts 02215, United States
  • University of Michigan Clinical Trials Office
    Ann Arbor, Michigan 48109, United States
  • Respiratory Medicine Research Institute of Michigan
    Ypsilanti, Michigan 48197, United States
  • UBMD Pediatrics
    Buffalo, New York 14203, United States
  • Northwell Health
    New York, New York 10028, United States
  • Mt Sinai Medical Center
    New York, New York 10029-6574, United States
  • University Of NC At Chapel Hill
    Chapel Hill, North Carolina 27599 9500, United States
  • Cincinnati Childrens Hospital MC
    Cincinnati, Ohio 45229-3039, United States
  • Childrens Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Unv of TX Southwestern Medical Center
    Dallas, Texas 75235, United States
  • Texas Childrens Hospital
    Houston, Texas 77030, United States
  • Seattle Allergy and Asthma Rsch
    Seattle, Washington 98115, United States
  • Novartis Investigative Site
    Brisbane, Queensland 4101, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3052, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1Y 4G2, Canada
  • Novartis Investigative Site
    Toronto, Ontario M3B 3S6, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1C5, Canada
  • Novartis Investigative Site
    Québec, Quebec G1V 4W2, Canada
  • Novartis Investigative Site
    Angers, France 49933, France
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Toulouse, 31400, France
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60596, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Sagamihara, Kanagawa 252-0392, Japan
  • Novartis Investigative Site
    Setagaya-ku, Tokyo 157-8535, Japan
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
  • Novartis Investigative Site
    Esplugues, Barcelona 08950, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
09

References and documents

Publications

  • Ghelli C, Costanzo G, Canonica GW, Heffler E, Paoletti G. New evidence in food allergies treatment. Curr Opin Allergy Clin Immunol. 2024 Aug 1;24(4):251-256. doi: 10.1097/ACI.0000000000000999. Epub 2024 May 30. PubMed 38814736 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Mar 2025, 22 months.

Results were first posted in Oct 2025, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Jan 10, 2023
StartActual
Apr 27, 2023
Primary completionActual
Mar 6, 2025
CompletionActual
Mar 6, 2025
Results first posted
Oct 30, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05678959
Responsible party
Sponsor
First posted
Jan 10, 2023
Start date
Apr 27, 2023
Primary completion
Mar 6, 2025
Completion
Mar 6, 2025
Results posted
Oct 30, 2025
Last update
Jan 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ligelizumab

Start the discussion